Mazor Robotics

buran und MfG  

:::::::::::: 10,63 $ +3,20% +0,33 $
In Euro: 7,8215 € | Nasdaq OTC Other, 03.01.14 ,GrB  

Branche Medizintechnik/-ausrüstung
  HerkunftIsrael
   Website mazorrobotics.com          §
Aktienanzahl§35,3 Mio. (Stand: 29.10.13)
 Marktkap.§374,8 Mio. $
GrB  

Zeit   Kurs Stück
  15:30:39§10,88 $ 100
  15:30:09§11,08 $ 400
_________________
GRATULATION  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  09.01.14     11,00     11,00§10,40 10,50 $ 10.265 107 T

GrB  

10.50 Down 0.50(4.55%) Jan 9, 2:17PM EST
Prev Close: 11.00
     Open:11.00
      Bid: N/A
      Ask: N/A§
1y Target Est: N/A
     Beta:       N/A§
Next Earnings Date: N/A
Day's Range: 10.40 - 11.00
52wk Range: 2.12 - 11.84
   Volume:    10,265§
Avg Vol (3m): 9,543
Market Cap: 368.96M
P/E (ttm): N/A
EPS (ttm): -0.66
Div & Yield: N/A (N/A)
http://finance.yahoo.com/q?s=MZRTF&ql=1  

Renaissance™

Next-generation System for Spine Surgery
Mazor Robotics Renaissance™ Guidance System is transforming spine surgery from freehand operations to highly-accurate, state-of-the-art procedures that may reduce fluoroscopy. It is the only mechanical guidance system for spine surgery with FDA clearance and CE marking.
Renaissance has been used in thousands of spine procedures worldwide ranging from minimally-invasive surgery to scoliosis and other complex spinal deformity cases.http://mazorrobotics.com/  

marketing of an innovative surgical guidance system for spine surgery and complementary products that provide a safer environment for patients, surgeons, and OR staff.

Mazor Robotics Renaissance(tm) Guidance System enables surgeons to conduct spine surgeries in a more accurate and secure manner. Mazor Robotics technology has been successfully used in the placement of tens of thousands of implants in the United States, Asia and Europe. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages.

Listed on the Tel-Aviv Stock Exchange since 2007 (TASE: MZOR) and recently listed on the NASDAQ (NASDAQCM: MZOR) in May of 2013,
Core technologies and clinical pipeline include mechanical guidance systems for spine and brain surgery, new procedures using these technologies, and medical 3D imaging for surgery.
Headquartered in Israel, Mazor Robotics has wholly-owned subsidiaries in the USA and Germany, as well as a growing network of international distributors
Mazor Robotics has 100 highly-qualified employees worldwide.
http://mazorrobotics.com/investor-relations/  

General Shareholders Meeting: January 21, 2014

Proxy Statement – January 14 2014 General Shareholders Meeting
http://mazorrobotics.com/investor-relations/shareholder-meetings/  

http://mazorrobotics.com/investor-relations/ir-conferences/ GrB  

http://mazorrobotics.com/investor-relations/investor-presentation/ GrB  

http://mazorrobotics.com/media/press-releases/ GrB  

for Renaissance™ System From Turkey Distribution Partner
CAESAREA, Israel – December 19, 2013 – Mazor Robotics Ltd. (NASDAQCM: MZOR; TASE: MZOR), the developer of Renaissance™, an innovative surgical guidance system and its complementary products, announced today that it has received its first order for a Renaissance system from Cordamed Biomedical Engineering Inc., its distribution partner in Turkey. This represents the first Renaissance system order in Turkey, and Cordamed will install the system at a prominent hospital in Istanbul.

“Our strategy of working with distributors is demonstrating tangible results, allowing us to expand our presence in key markets,” commented Ori Hadomi, Mazor’s Chief Executive Officer.  “Our Renaissance system enables hospitals to improve patient care with a leading technology, thus raising the standard of the care.”

“The Cordamed team is highly skilled and motivated to ensure the healthcare system throughout Turkey is utilizing the latest technologies to provide better surgery outcomes,” commented Bayram Kose, Chief Executive Officer of Cordamed.  “The clinical success to date of the Renaissance system, could create additional opportunities in Turkey as healthcare facilities seek to raise the standard of care.”

Cordamed has been focused on the minimally invasive surgery (MIS) market since 2006, representing a new generation of medical device companies that have developed leading technology products.  Through its analytical experiences in biomedical engineering and a highly experienced post-sales assistance team, it has exclusive distribution rights for most of the robotic surgical systems that improve the quality of healthcare services standards in Turkey.

About Mazor
Mazor Robotics is dedicated to the development and marketing of innovative surgical robots and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance™, is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 35,000 implants worldwide. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology.  For more information, the content of which is not part of this press release, please visit www.mazorrobotics.com, the content of which does not form a part of this press release.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the the expansion of Mazor into key markets, the clinical and economic benefits of Renaissance, additional opportunities in Turkey, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements.  These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC), including those discussed under the heading “Risk Factors” in Mazor’s registration statement on Form F-1 filed with the SEC on and in subsequent filings with the SEC.  For more details, refer to Mazor’s SEC filings and the amendments thereto. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.


U.S. Contacts: EVC Group
Michael Polyviou/Robert Jones – Investors
mpolyviou@evcgroup.com; bjones@evcgroup.com
(212) 850-6020; (646) 201-5447

John Carter – Media
jcarter@evcgroup.com
(212) 850-6021

HomeRenaissance™PhysiciansAbout UsNewsInvestor Relationhttp://mazorrobotics.com/...-system-from-turkey-distribution-partner/  

Mazor Robotics Announces Two Renaissance Systems orders in the U.S. and International Markets

Seven New Renaissance Systems Ordered in the 2013 Fourth Quarter; Enters 2014 with Install Base of 63 Systems

CAESAREA, Israel–(BUSINESS WIRE)– Mazor Robotics Ltd. (TASE: MZOR; NASDAQCM: MZOR), the developer of Renaissance™, an innovative surgical guidance system and its complementary products, announced today orders of two Renaissance systems in late December, ending the 2013 fourth quarter with a total of seven system sales. In the U.S., the system was ordered by Littleton Adventist Hospital (Littleton, CO) and the second system was ordered internationally by Bestech, the Company’s distributor in Israel, for installation in a hospital in Haifa, Israel.

Littleton Adventist Hospital purchased its first Renaissance system becoming the fifth Adventist Health System hospital and the second hospital within the Centura Health system to purchase a Renaissance system. Littleton Adventist Hospital is a full-service medical center that has provided compassionate health care and quality treatment for more than 20 years. The hospital’s medical teams specialize in cardiology, orthopedics, neurology, cancer care and women’s and children’s services.

Bestech, the Company’s distribution partner in Israel, has installed the Renaissance system at Bnai Zion Medical Center, located in Haifa, Israel. Established in 1922 as the first Jewish hospital in Haifa, Bnai Zion Medical Center focuses on rehabilitation activities, offering orthopedic rehabilitation, neurological rehabilitation, cardio rehabilitation, physical therapy and occupational therapy.

“Our momentum, both in the U.S. and internationally, and the purchase of these Renaissance systems demonstrates the continued support and interest which surgeons and hospital administrators express toward our technology,” commented Ori Hadomi, Chief Executive Officer. “We expect these hospitals to experience positive clinical and business benefits, similar to the other hospitals.”

About Mazor
Mazor Robotics (TASE: MZOR; NASDAQCM: MZOR) is dedicated to the development and marketing of innovative surgical robots and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance™, is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 35,000 implants worldwide. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, the content of which is not part of this press release, please visit www.mazorrobotics.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the clinical and economic benefits of Renaissance, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC), including those discussed under the heading “Risk Factors” in Mazor’s registration statement on Form F-1 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings and the amendments thereto. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

Contacts

U.S.:
EVC Group
Michael Polyviou/Robert Jones – Investors
212-850-6020; 646-201-5447
mpolyviou@evcgroup.com; bjones@evcgroup.com
John Carter – Media
212-850-6021
jcarter@evcgroup.com
http://mazorrobotics.com/...ers-in-the-u-s-and-international-markets/  

2012
2012 Financial Statements 31 December 2012 (English)
2012 Annual Report 31 December 2012 (Hebrew)
Q3 2012 Interim Report 31 September 2012 (English)
Q3 2012 Interim Report 31 September 2012 (Hebrew)
Q2 2012 Interim Report 31 June 2012 (English)
Q2 2012 Interim Report 31 June 2012 (Hebrew)
Q1 2012 Interim Report 31 March 2012 (English)
Q1 2012 Interim Report 31 March 2012 (Hebrew)

2011
2011 Financial Statements 31 December 2011 (English)
2011 Annual Report 31 December 2011 (Hebrew)
Q3 Interim Report 30 September 2011 (English)
Q3 Interim Report 30 September 2011 (Hebrew)
Q2 Interim Report 30 June 2011 (Hebrew)
Q1 Fincancial Report 31 March 2011 (English)
Q1 Interim Report 31 March 2011 (Hebrew)

2010
2010 Annual Report 31 December 2010 (Hebrew)
2010 Annual Report 31 December 2010 (English)
Q3 Interim Report 30 September 2010 (Hebrew)
Q2 Interim Report 30 June 2010
(Hebrew)
Q1 Interim Report 31 March 2010 (Hebrew)

2009
2009 Annual Report 31 March 2009 (Hebrew)

Normal 0 false false false EN-US X-NONE HE MicrosoftInternetExplorer4 2011 Financial statementshttp://mazorrobotics.com/investor-relations/financial-reports/  

for
Mazor Robotics (MZOR)

U.S Securities and Exchange Commission

All TASE Regulatory filings can be found on the
website of the Tel Aviv Stock Exchange
Tel Aviv Stock Exchangehttp://mazorrobotics.com/investor-relations/regulatory-filings/  

Sharon Levita, CFO  
Mazor Robotics Ltd.
Office: +972-4-6187103
Cell: +972-54-6921335

sharon.levita@MazorRobotics.com


U.S. Investor Relations
Robert Jones,
bjones@evcgroup.com 646-201-5447
Michael Polyviou,
mpolyviou@evcgroup.com   732-232-6914
http://mazorrobotics.com/investor-relations/ir-contact/  

DEVELOPER OF AN INNOVATIVE SURGICAL ROBOTS.
  Issuer No.  
Corporate No.
  Market Cap (09/01/2014)  
  1487  
  513009043  
   1,551,986 NIS thousands  

  TASE Supersector
  TASE Sector  
  TASE Subsector  
  Indices  
  High-Tech  
  Biomed  
  Medical Devices  
  TA75 Index, TA100 Index, TA-Biomed Index, TA BlueTech-50 Index, TA Composite Index, Additional Indiceshttp://www.tase.co.il/eng/general/company/pages/...p;companyID=001487  

   Symbol:                    §
      MZOR§Dual-Listed Company Market Maker Appointed for Security  
     ISIN:§ IL0011068553
Security Type : Share
http://www.tase.co.il/eng/general/company/pages/...p;companyID=001487  

Closing Price (0.01 NIS)
3,802
Change(%) -3.75%
Turnover (NIS)
13,512,470
Trans.
1,506
Capital Listed for Trading
40,820,245
Market Cap (NIS thousands)
1,551,986
Base Price
3,950
Opening Price
3,850
High
3,850
Low
3,732
Yield MTD (%) 13.5%
Yield YTD (%) 13.5%
CUSIP 57886P202
Foreign Stock Exchange NASDAQ-CM
http://www.tase.co.il/eng/general/company/pages/...p;companyID=001487  

Date Closing Price (0.01 NIS) Adjusted Closing Price* Change (%) Base Price Opening Price High Low Turnover (NIS)
09/01/2014
3,802
3,802
-3.75%
3,950
3,850
3,850
3,732
13,512,470§
08/01/2014
3,950
3,950
-1%
3,990
4,001
4,167
3,950
20,425,924§
http://www.tase.co.il/eng/general/company/pages/...p;companyID=001487  

AM

1/2/2014 4:17 PM Other Report or Announcement
12/24/2013 12:51 PM Event
12/19/2013 11:38 AM Other Report or Announcement
12/17/2013 11:15 AM Other Report or Announcement
12/16/2013 7:49 AM Event
http://www.tase.co.il/eng/general/company/pages/...p;companyID=001487  

reports on Mazor Robotics. Please note that this list is subject to change and that any estimates, forecasts, or opinions are made by the analysts alone and do not represent the estimates, forecasts, or opinions of Mazor Robotics or its management.
Jeffrey S. Cohen
Ladenburg Thalmann & Co. Inc.
Office: 305-572-4110
jcohen@ladenburg.com
Kathleen McGrath
WallachBeth Capital LLC
Office: 646-998-7607
kmcgrath@wallachbeth.com
Gregory Chodaczek
First Analysis Securities Corporation
(312) 258-7116
GChodaczek@firstanalysis.com
Jose T. Haresco III, Ph.D.
JMP Securities, LLC
(415) 869-4477
JHaresco@jmpsecurities.com
Matt Taylor
Barclays
(212) 526-6965
matthew.c.taylor@barclays.com
http://mazorrobotics.com/investor-relations/analyst-coverage/  

:::::::::::::::: 10,82 $ +3,05% +0,32 $
In Euro: 7,9161 € | Nasdaq OTC Other, 10.01.14:::::::: und so manana ..::hoooaaaaa

buran,Die Börsen RUSSIAN Mazor Robotics WODKA Tüffe
 

:::::::::::::::::: 11,89 $ +5,41% +0,61 $
In Euro: 8,7431 € | Nasdaq OTC Other, 14.01.14::::: datt mir nen EUR Stück die Prägung verliert hier ..umpa umpa täätääräääääääää

buran,Der Börsen Ticker MAZOR